Developed and validated stability indicating HPLC method for the determination of epirubicin in bulk drug, marketed injection and polymeric nanoparticles by Tariq, Mohammad et al.
Braz. J. Pharm. Sci. 2018;54(4):e17515 Page 1 / 9
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902018000417515
A
rt
ic
le
*Correspondence: S. Talegaonkar. Delhi Pharmaceutical Science and 
Research University, New Delhi, India. Phone: +91-9818453518. E-mail: 
stalegaonkar@gmail.com
Developed and validated stability indicating HPLC method for the 
determination of epirubicin in bulk drug, marketed injection and 
polymeric nanoparticles
Mohammad Tariq1, Shindu Thomas2, Anu Singh3, Sushama Talegaonkar2,4*
1Tech Observer India Private Limited, New Delhi, India, 2Department of Pharmaceutics, School of Pharmaceutical Education 
and Research, (SPER), Jamia Hamdard, New Delhi, India, 3Dabur Research Foundation, Sahibabad, Ghaziabad, India, 
4Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), Pushp Vihar, New Delhi, 
India
Present work is aimed to develop a simple, sensitive, robust and reliable HPLC method for routine quality 
control of epirubicin (EPI) in bulk drug, marketed injections and polymeric nanoparticles. Separation was 
carried out by C18 column. Isocratic elution was carried out using mobile phase A: 0.16% o-phosphoric 
acid solution, B: acetonitrile and methanol mixture (80:20, v/v) in the ratio of 60:40 (A: B) while the 
flow rate was maintained at 1mL/min. Analyses were performed at 233.5 nm using PDA detector. 
Excellent linear relationship was observed between peak-area versus drug concentration in the range of  
1.0‑100.0 μg/mL (r2, 0.999). Developed method was found to be sensitive (Limits of detection and 
quantification were found to be ~8 ng/mL and ~25 ng/mL, respectively), precise (RSD <1.0%, for 
repeatability and <2.0% for intermediate precision, within acceptable ranges of precision), accurate 
(recovery in different dosage form, 94.65 ‑100.26%, within acceptable range, 80‑120%), specific and 
robust (% RSD <2, for system suitability parameters). Stress‑induced degradation studies demonstrated 
that method can suitability be applied in the presence of degradants. Developed method has been 
successfully applied for the determination of entrapment efficiency, drug loading, in vitro release profile, 
in vitro permeation studies as well as stability assessment of polymeric nanoparticles. 
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INTRODUCTION 
Epirubicin (10-(4-amino-5-hydroxy-6-methyl-
oxan-2-yl)oxy-6,8,11-trihydroxy-8-(2hydroxy acetyl)-
1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione) is 
an anthracycline anticancer agent which is used for the 
treatment of node positive breast cancer, ovarian cancer, 
gastric cancer, lung cancer and lymphomas (Neil, 2006). 
Epirubicin is obtained by chemical transformation of a 
substance produced by certain strains of Streptomyces 
peucetius (Neil, 2006). It acts by forming a complex with 
DNA by intercalation into nucleotide base pairs thus 
hindering DNA and RNA synthesis (Omrod et al., 1999). 
It is favoured over doxorubicin as it is found to be less 
toxic at equimolar dose which may be due to the different 
spatial orientation of the hydroxyl group at the 4’ carbon 
of the sugar moiety results in opposite chirality which 
leads to its faster elimination and reduced toxicity (Neil, 
2006; Sweetman, Martindale, 2007). It is available as 
intravenous injection but due to sudden rise in the blood 
level and rapid elimination often to sub therapeutic levels 
necessitates frequent dosing leading to a serious adverse 
effect. Hence, we formulated polymeric nanoparticles 
delivery system, to achieve  controlled drug release, which 
will not only limit the side effects but also help in reducing 
dose and dosing frequency. With the advancement in 
nanotechnology-based delivery system and their complex 
pharmacokinetics requires a stringent quality control of 
these dosage forms to maintain its safety and efficacy. At 
present, EPI is being used extensively in clinical practice 
and therapy. Therefore, accurate and validated analytical 
method is required for quantitative analyses of EPI in 
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bulk drug, marketed injection, polymeric nanoparticles, 
in-vitro as well as in biological samples. Several analytical 
methods such as LC/MS-MS (Wall et al., 2007; Sottani 
et al., 2009), LC equipped with UV (Dodde et al., 2003; 
Badea et al., 2005), fluorescence (Dine et al., 1990), and 
electrochemical detector (Ricciarello et al., 1998) have 
been reported so far for analysis of EPI in biological fluids. 
These analytical methods (LCMS, Fluorescence detection) 
are more sensitive and accurate, however expensive, 
hence, limit their utility in the routine quality control of 
pharmaceutical dosage forms. In addition, no method has 
been reported so far for quantitative analysis of epirubicin 
in polymeric nanoparticles. 
In the given study, a simple, rapid, sensitive and 
accurate HPLC-UV method is developed which is capable 
of detecting and quantifying minute quantity of drug 
accurately and precisely with a short run time in bulk 
drug, marketed formulation, polymeric nanoparticles, and 
in-vitro studies sample which may be further extended to 
in-vivo biological fluids such as plasma, serum etc. Here, 
the method is validated for accuracy, precision, selectivity, 
sensitivity and various other validation parameters as per 
ICH guidelines. 
MATERIAL AND METHODS
Instrumentation and chromatographic conditions 
The liquid chromatographic system e2695 separation 
module (Waters Alliance, Milford, MA, USA) equipped 
with a gradient flow control pump, online solvent degasser, 
auto-sampler, PDA detector 2998, column manager and 
pre-column heater was used for the analysis. All the 
parameters of HPLC were controlled by LC solutions 
software Empower 2. Chromatographic separations were 
obtained by using Purosphere® C18 (5 µm, 250*4.6 mm) 
column, which was maintained at 30 ºC. Ten microliters of 
sample was injected into HPLC system. Isocratic elution 
was carried out using mobile phase which is the mixture of 
aqueous phase (A, 60 v/v) and organic phase (B, 40 v/v). 
Aqueous phase (A) comprising of 0.16% O-Phosphoric 
acid solution while organic phase (B) comprising of 
acetonitrile and methanol mixture (80:20). The flow rate 
was maintained at 1mL/min. The mobile phase was filtered 
through 0.45 μm filter (Sartorius, Germany) and deaerated 
for 15 min by sonication before injecting into the system 
and column was allowed to equilibrate for 20 min with the 
mobile phase. All samples were analyzed at wavelength of 
233.5 nm for a total run time of 12 min. Data acquisition 
and data handling were performed by Empower Software 
v2.0. Developed method was validated for parameters like 
precision, accuracy, robustness, specificity, sensitivity, 
linearity as described in ICH guidelines (ICH, 2005).
Method development 
Preparation of stock and standard solutions
Ten milligrams of EPI was accurately weighed and 
transferred to a 10 mL volumetric flask and dissolved in 
methanol followed by sonication and subsequently filtered 
through 0.45 μm filter to get a stock solution, 1 mg/mL. 
Stock solution was further diluted to obtain the required 
concentrations (1‑100 μg/mL) before injecting into the 
system for analyses. Quality control samples at three 
levels, low (2 μg/mL), intermediate (10 μg/mL) and high 
(50 μg/mL) were also prepared in the same way. 
Method validation 
The developed method was validated for linearity 
range, precision, accuracy, robustness, limit of detection 
(LOD) and limit of quantification (LOQ) as per ICH 
guidelines (ICH, 2005).
System suitability
For the assessment of system suitability, 10 μL of 
epirubicin solution (10 μg/mL, n=6) were injected and 
system suitability parameters like retention time, peak 
area, theoretical plates and tailing factor were calculated 
and compared with standard accepted values. 
Linearity
A 7-point calibration curve was constructed in a 
concentration range of 1-100 µg/mL for linearity. The 
mean peak area of epirubicin was plotted against its 
concentration and linear least square regression analysis 
was performed. 
Limit of detection and limit of quantification 
Limit of detection (LOD) and limit of quantification 
(LOQ) were determined based on the signal to noise ratios 
(s/n) using analytical responses of three and ten times of 
the background noise, respectively using the following 
equation, s/n ratio was calculated through Empower 
software version 2 (Warsi et al., 2011; Tariq et al., 2015a).
 
 
Precision
Precision of the methods was determined in terms of 
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intra-day and intermediate precision. Intra-day precision 
(Repeatability) of developed method was determined by 
analyzing quality control samples (2 µg/mL, 10 µg/mL, 
50µg/mL, each 6 replicates) using identical test material, 
identical analytical method and similar experimental 
conditions over a short period. Results were analyzed by 
identical evaluation method. Intermediate precision was 
determined on different days, rest of the conditions was 
followed as described for intra-day precision. Intra-day 
and intermediate precision were expressed as relative 
standard deviation (RSD, %). 
Accuracy
Accuracy of the developed method was assessed 
by assaying 9 samples. Test samples (100 µg/mL claimed 
amount) were spiked with 3 levels of claimed amount i.e. 
low (LQC, 50 µg/mL), medium (MQC, 100 µg/mL) and 
high (HQC, 150 µg/mL). Accuracy was determined as 
following and expressed in terms of % recovered; 
Robustness
Robustness of method was determined by changing 
pH of mobile phase, column temperature and column 
manufacturer. The robustness of methods was expressed 
as RSD (%) for system suitability parameters like peak 
areas, RT, and peak tailing.
Forced degradation studies 
The specificity of the method was determined by 
exposing drug solution of known concentration (100 μg/mL) 
to different conditions like acidic (0.1 M HCl for 24 h), 
basic (0.1 M NaOH for 24 h), oxidizing (30% H2O2 v/v 
for 24 h), photolytic degradation (for 24 h), and thermal 
stress at 50 ºC for 24 h (Tariq et al., 2014). The resulting 
solutions were diluted and processed accordingly and 
analyzed for the drug peak as well as degradation product. 
Applications of method
Epirubicin loaded poly-lactide-co-glycolic acid 
nanoparticles (EPI-NPs) were prepared by double 
emulsion solvent evaporation as described in our previous 
report (Tariq et al., 2014). 
Determination of entrapment efficiency and drug 
loading 
Entrapment efficiency and drug loading was 
calculated as following;
In vitro Release Profile
In vitro release study was performed by dialysis 
bag method and compared with free drug solution. EPI 
(2 mg) and EPI-NPs (equivalent to 2 mg EPI) were 
suspended into 5 mL dissolution media and poured into 
dialysis bag ((MWcut off of 8–10 kDa, Spectra/Por®) 
and subsequently dialysis bag was dipped into 50 mL of 
dissolution media. Study was carried at 37 ºC and 100 rpm 
under magnetic stirrer. Samples were withdrawn at regular 
time interval and analyzed by HPLC. 
In vitro permeation study
EPI is a substrate for both P-glycoprotein (P-gp) and 
cytochrome P450 (CYP 450), and also highly hydrophilic 
in nature hence elicits poor oral bioavailability. Therefore, 
epirubicin loaded PLGA NPs were developed to improve 
oral bioavailability. Developed formulation was evaluated 
for in-vitro permeation profile by using Caco‑2 cell line 
model and intestinal gut sac method as previously reported 
(Tariq et al., 2015b).
For cellular transport study, cells (105/insert) were 
grown on polycarbonate membrane filters with 0.4 µm pore 
size and 1.12 cm2 growth area. Only cell monolayers with 
TEER values over 300 Ω cm2 were included in the study. 
Transport of EPI-S and EPI-NPs was studied in the apical 
to basal direction. For the purpose, 0.5 mL of test solutions 
(diluted with serum free growth media) were added to apical 
side whereas 1.5 mL of serum free growth media was added 
to basolateral side. At each time point, 0.2 mL samples from 
basolateral side were withdrawn and stores at -20 °C. 
For intestinal permeation study, Ileum (5-7 cm) was 
washed with saline followed by ligation of on end while 
other end was mounted on assembly use to conduct the 
study. Ileum sac was filled with EPI‑S solution (1 mL, 
100 µg/mL) or EPI-NPs suspension (equivalent to 
100 µg of EPI in 1 mL) and suspended into pre-warmed 
(37 ± 0.5 °C) and pre-oxygenated Tyrode’s buffer 
(10 mL). Samples (0.5 mL) were withdrawn defined time 
intervals,15, 30, 45, 60, 75, 90 min and stored at -20 °C. 
Samples of cellular and intestinal transport studies 
were analyzed by HPLC and permeation data was 
expressed as flux (Jss, μg/cm2/h). 
Stability studies of EPI-NPs as per ICH guidelines 
Stability study of (EPI-NPS) was carried out as per 
ICH Q1A (R2) guidelines (ICH, 2003). Formulation was 
M. Tariq, S. Thomas, A. Singh, S. Talegaonkar
Braz. J. Pharm. Sci. 2018;54(4):e17515Page 4 / 9
subjected to 5±3 ºC (long term study) and 25±2 ºC and 
60±5% RH (accelerated storage condition) for a period 
of six months. Samples were analyzed at regular time 
intervals 0, 30, 60, 90, and 180 days for the change in their 
drug content by HPLC. 
RESULTS AND DISCUSSIONS
Method development
In the present study, various parameters like column, 
mobile phase composition, mobile phase ratio, flow rate 
and its pH were optimized to obtain a good peak shape 
with high resolution, symmetry and reproducibility. 
Columns such as Supelco® and Purosphere® were 
used and the best peak was obtained with Purosphere®. 
Different mobile phases were tried such as acetonitrile‑
water, methanol-water, and mixture of acetonitrile: 
methanol and water. As the epirubicin hydrochloride is 
an ionizable compound hence best peak was expected at 
lower pH therefore pH adjusted (pH 3) with phosphoric 
acid which resulted in best peak with good symmetry and 
high resolution. Thus, best peak and low retention time 
was obtained with 0.16% aqueous o-phosphoric acid 
solution (A) and mixture of acetonitrile: methanol, 80:20 
v/v (B) when isocratic elution was carried out at the mobile 
phase ratio of 60:40 (A:B). The flow rate was maintained 
at 1mL/min. All the above optimized parameters produced 
a peak with good shape and very short retention time, 
4.52±0.3 min (Figure 1) which is the lowest retention time 
of all the methods developed so far in our belief. However, 
the total run time was 12 min, giving an additional time for 
complete elution of excipients and degradation products 
to avoid carry over peak in the next injections.
Method validation
System suitability
System suitability was evaluated by six replicated 
injections at a concentration of 10 μg/mL and system 
suitability parameters were summarized in Table I. All the 
parameters met the acceptance criteria (USP) and relative 
standard deviation for individual parameters was found to 
be less than 1%. 
Linearity 
The linearity of an analytical method is its capability 
(within a given range) to achieve test results which are 
directly proportional to the concentration (amount) of 
analyte in the sample. Linearity of method was determined 
by calibration plot constructed between peak area and analyte 
concentration (Table II and Figure 2). The linear regression 
data over the concentration range of 1-100 µg/mL was 
found to be within 95% confidence limit with a correlation 
coefficient (r2), 0.999 which confirmed the excellent 
linearity of developed method in the range (Table II). 
FIGURE 1 - Overlay of representative chromatograms of epirubicin.
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Limit of detection and limit of quantification 
Kurbanoglu et al. (2013) reported LOQ for 
epirubicin 27 ng/mL and LOD and LOQ were found to 
be 8ng/mLand 25 ng/mL for our developed method which 
indicated that the developed method is more sensitive 
than previous one. Sensitivity of any analytical method 
is expressed in term of limit of detection and limit of 
quantification (LOD and LOQ). LOD represents the lowest 
amount of analyte that can be detected but not quantified 
precisely, while LOQ represents the quantity of analyte 
which can be quantified accurately and precisely. Low 
values of LOD (8 ng/mL) and LOQ (25 ng/mL) reflect 
that the developed method is sensitive.
Precision
Table III summarizes repeatability and intermediated 
precision which were found to be <1% and <2%, 
respectively. Both repeatability and intermediated 
precision were within the acceptance limit (ICH, 2005), 
thus developed method is said to be precise. Precision 
represents random error i.e. errors which occur at any 
point of analysis from sampling to calculation. It can 
be determined at 3 levels i.e. repeatability (Intra-day 
precision 1st level), intermediate precision (2nd level) and 
reproducibility (3rd level). Repeatability is determined over 
a short period of time under similar test concentration, 
materials, method and experimental conditions while 
intermediate precision is determined on different 
days, by different analysts using different equipment. 
Reproducibility represents inter-laboratory precision, 
usually not considered as a part of analytical validation 
until unless developed method is meant for analytical 
transfers. Hence, precision was determined in terms of 
repeatability and intermediate precision only.
Accuracy 
Accuracy of a method is defined as closeness between 
the experimentally measured value and the true value. 
Difference between experimentally measured value and true 
value represents the systematic error or bias of a method 
in the presence of excipients/formulation components. 
Accuracy of method was determined as % recovered 
TABLE I - System suitability (n=6)
Peak area RT UPS tailing HETP
348533 4.548 0.94 3223
350123 4.503 0.92 3312
352437 4.528 0.93 3245
345673 4.539 0.94 3284
349896 4.511 0.92 3305
351001 4.55 0.92 3213
Mean 349611 4.53 0.93 3263.7
SD 2320.85 0.02 0.01 42.49
RSD 0.66 0.43 1.06 1.30
TABLE II - Linear regression data for calibration plots
Parameters Regression Values
Linearity range 1-100 µg/mL
Regression equation Y=37712 X ‑27028
Correlation coefficient (r2) 0.999
Slope 37712
Intercept -27028
FIGURE 2 - Calibration plot of epirubicin hydrochloride 
(concentration range 1‑100 μg/mL).
TABLE III - Intra‑day and inter‑day precision (n=6)
Theoretical Conc.
(μg/mL)
Intra-day precision Inter-day precision
Mean Conc. (μg/mL) % RSD Mean Conc. (μg/mL) % RSD
2 (LQS) 2.094±0.01 0.48 2.08±0.03 1.63
10 (MQS) 9.87± 0.05 0.55 9.88± 0.135 1.36
50 (HQS) 49.11±0.215 0.43 49.28±0.50 1.0
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amount after spiking 50%, 100%, and 150% of claimed 
concentration of bulk drug, the marketed injection and 
PLGA NPs sample. These samples were analyzed by the 
proposed method and results were expressed in term of % 
recovered, % CV and bias (Table IV). The % recovery of 
epirubicin was obtained in the range of 94.65 -100.26% 
which was within the acceptance range 80-120% (ICH, 
2005). Thus, method can be said accurate.
Robustness
Method was also evaluated for its robustness by 
measuring its capacity to remain unchanged through 
putting little but intentional variations in method’s 
parameters. Robustness of the method was determined 
by calculating RSD (%) of system suitability parameters 
(Table V) after making deliberate changes in column, 
column temperature and mobile phase pH, no substantial 
change was observed in system suitability parameters (% 
RSD< 2) which confirmed the consistency of developed 
method during normal usage. 
Forced degradation studies 
Forced degradation studies were performed to 
determine the specificity of the analytical method. In 
this study, the developed method was found able to 
clearly separate the analyte peak and the degradation 
products (Table VI). Chromatograms obtained after 
forced degradation study (acid, base, photo, oxidative, 
thermal stress) demonstrated separate peaks of analyte 
and degradants, which indicated the specificity of the 
developed method. Epirubicin was found to be most 
resistant to acid treatment while highly sensitive to alkali 
treatment (Figure 3). 
Applications of method
For the development and optimization of epirubicin 
loaded PLGA NPs, various formulation parameters like 
polymer type, polymer concentration, drug-polymer ratio, 
sonication time, stabilizer type, stabilizer concentration, 
TABLE IV - Accuracy as % recovery (n=3)
Dosage form Label claimed (µg) Amount added (µg) % recovered % CV Bias
Bulk drug
100 50 99.45±.16 0.156 -0.55
100 100 99.89±0.08 0.087 -0.11
100 150 100.026±0.29 0.29 0.027
Marketed Injection
100 50 95.32±2.83 2.97 -4.68
100 100 96.15±1.62 1.69 -3.85
100 150 96.68±2.9 3.0 -3.32
PLGA NPs
100 50 92.22±2.8 2.80 -7.77
100 100 92.89±1.93 1.93 -7.11
100 150 94.65±1.93 1.93 -5.35
TABLE V - Robustness (n=3)
Parameter evaluated
Peak area 
(% RSD)
RT 
(%RSD)
Tailing 
(% RSD)
Column 
Purosphere®
1.26 0.209 1.26
Supelco®
Temperature
25 ºC
1.37 0.53 0.76
30 ºC
pH
3.0
1.55 0.51 0.65
3.5
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volume of internal aqueous phase etc. were studied to see 
their effect on the entrapment efficiency and drug loading 
of NPs. Entrapment efficiency was found to be in the range 
of 11.5-44.12% while the drug loading was found to be in 
the range of 1.13-4.34%. 
In-vitro release study of free epirubicin solution 
showed a very fast release i.e. drug diffused out completely 
within an hour while epirubicin loaded PLGA NPs 
demonstrated sustained biphasic release pattern, initially 
~20% of total loaded drug was diffused out in first 2 h and 
remaining thereafter i.e. ~85% in 48 h. Burst effect can be 
explained by high drug solubility in dissolution media and 
availability of drug molecules at the surface which leached 
out rapidly while sustained release can be attributed to 
existence of drug molecules at the core of hydrophobic 
polymer matrix.
Epirubicin loaded PLGA NPs demonstrated better 
permeation profile (Jss 0.63 μg/cm2.h) over free drug 
solution (Jss 0.23 μg/cm2.h) across Caco-2 cell line. 
Similarly, better permeation profile of epirubicin across 
rat ileum through NPs (Jss 1.0 μg/cm2.h) was observed 
when compared with free solution (Jss, 0.223 μg/cm2.h). 
Significantly high flux across the Caco-2 cell line and 
rat ileum (p<0.001) through NPs can be attributed to 
encapsulation of drug into NPs provided protection to it 
from P-gp, and CYP-450. In addition, endocytic uptake 
of particles improved the permeation. 
Figure 4 summarizes stability data. Six-month 
stability profile demonstrated no significant change in 
assay at both long-term condition, 5±3 ◦C (~1.8%) and 
accelerated storage condition, 25±2 ◦C, 60±5% RH 
(~2.5%). As per the ICH guidelines (Q1A R2), more than 
TABLE VI - Stress induced degradation studies
Stress conditions % Mean Recovered ± SD Figure
Untreated Sample 100 4a
HCl (0.1M) 24 h 98.32±0.87 4b
NaOH (0.1 M) 24 h 0.0% 4c
Daylight, 24 h 90.23±0.96 4d
H2O2 (30%, v/v), 24 h 87.36±0.91 4e
Thermal treatment (50 °C, 24 h) 82.16±1.01 4f
FIGURE 3 - Chromatograms obtained from forced degradation studies; a) Pure epirubicin hydrochloride; b) acid treatment; c) 
alkali treatment; d) Photo treatment; e) Oxidative treatment; f) Thermal treatment.
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5% change in assay is considered “significant” at any 
sampling point during 6 months at accelerated conditions 
(ICH, 2003). Thus, formulation can be considered stable. 
CONCLUSION
A simple and sensitive HPLC method for the 
quantitative estimation of epirubicin was successfully 
developed. Statistical assessment of methods proved that 
the developed method is specific, precise, and accurate and 
can be used successfully for the quantitative estimation 
in bulk drug, marketed formulation and polymeric 
nanoparticles for routine quality control of said dosage 
form. Stress induced degradation studies disclose the 
suitability of method for the quantification of drugs in 
the presence of degradants. The developed method has 
been successfully applied for the estimation of drug 
loading, entrapment efficiency, in vitro release profile, 
in vitro permeation profile and stability of the developed 
polymeric nanoparticles.
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